In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Analysing the top 10 tech company logos, we can understand the art and science behind creating visual identities that stand out from the crowd. Most people scroll past logos like they're invisible.

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be implemented over the next 18 months. Published first ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares opened today ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

10 luxury brand logos have mastered it. They've become more than marks on products—they're cultural touchstones, over decades and continents. Logos are stories we tell ourselves. The best ones?

I’m yet to invest in the stock as I already hold shares in Reckitt and GSK. However, I think it’s a good long-term investment to consider and one I’ll be keeping an eye on this year.

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

In a famously cyclical sector, I’d be daft to sell when the shares are down. Long-term GSK investors can be forgiven for feeling grumpy. The stock’s down 18% on a decade ago. And although ...